EYSUVIS (loteprednol etabonate)
Eysuvis is a corticosteroid used for the short-term relief of signs and symptoms associated with dry eye disease. It helps patients manage these issues for a duration of up to two weeks. This medication is typically prescribed to address the inflammatory components of the condition.
How EYSUVIS Works
This medication works by binding to and activating glucocorticoid receptors to inhibit the inflammatory response. It limits several processes associated with inflammation, such as edema, capillary dilation, and leukocyte migration. Additionally, it is thought to work by inhibiting the production of prostaglandins.
Details
- Status
- Prescription
- First Approved
- 2020-10-26
- Patent Cliff
- 2033
- Routes
- OPHTHALMIC
- Dosage Forms
- SUSPENSION/DROPS
EYSUVIS Approval History
What EYSUVIS Treats
1 indicationsEYSUVIS is approved for 1 conditions since its original approval in 2020. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Dry Eye Disease
EYSUVIS Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in EYSUVIS's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications EYSUVIS treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to EYSUVIS
3 of 5FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
12 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT04555694 results posted | TC-2020-DexRes | Ph 4 | completed | Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax |
| NCT01437982 | 628 | Ph 4 | completed | A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% |
| NCT01443442 results posted | MAC-06-11 | Ph 4 | completed | Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis |
| NCT01475643 results posted | 670 | Ph 3 | completed | Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children. |
| NCT03098953 | 881 | Ph 1 | completed | Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Installations |
| NCT01853696 results posted | 2013-0424 | Ph 4 | completed | Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty |
| NCT00699153 results posted | 526 | Ph 3 | completed | Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery |
| NCT00705159 results posted | 550 | Ph 4 | completed | Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis |
| NCT02028312 | CEI.HER-002 | Ph 4 | withdrawn | A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis® |
| NCT01724892 | othana001 | Ph 4 | completed | Comparison the Effects of Dexamethasone and Loteprednol on Epithelial Healing |
| NCT01060072 results posted | 577 | Ph 3 | completed | Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery |
| NCT01010633 results posted | 576 | Ph 3 | completed | Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
EYSUVIS FDA Label Details
Indications & Usage
FDA Label (PDF)EYSUVIS is indicated for the treatment of Dry Eye Disease.
EYSUVIS Patents & Exclusivity
Patents (17 active)
Pro Intelligence Preview
Deep insights for EYSUVIS
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2033
- • 17 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 5 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.